Insider Transactions in Q1 2024 at Theravance Biopharma, Inc. (TBPH)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2024
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
BUY
Bona fide gift
|
Indirect |
3,900
+50.0%
|
-
|
|
Mar 15
2024
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Bona fide gift
|
Direct |
10,900
-0.35%
|
-
|
|
Mar 15
2024
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,704
+0.17%
|
$21,632
$8.64 P/Share
|
|
Feb 22
2024
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Open market or private sale
|
Direct |
1,254
-0.4%
|
$10,032
$8.71 P/Share
|
|
Feb 20
2024
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
37,196
-2.33%
|
$297,568
$8.92 P/Share
|
|
Feb 20
2024
|
Aine Miller SVP, DEV & HEAD OF IRE OFFICE |
SELL
Payment of exercise price or tax liability
|
Direct |
11,782
-8.11%
|
$94,256
$8.92 P/Share
|
|
Feb 20
2024
|
Aziz Sawaf SVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
17,036
-6.66%
|
$136,288
$8.92 P/Share
|
|
Feb 20
2024
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Payment of exercise price or tax liability
|
Direct |
18,219
-5.5%
|
$145,752
$8.92 P/Share
|
|
Feb 20
2024
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
19,294
-5.77%
|
$154,352
$8.92 P/Share
|
|
Feb 20
2024
|
Brett A. Grimaud SVP, GEN COUNSEL AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
17,595
-6.32%
|
$140,760
$8.92 P/Share
|